FDA Approves Chlorascrub(TM) Swab Skin Antiseptic for Inclusion in Kits

PDI®, the leader in wet wipe infection prevention, education and patient care announces the approval of Chlorascrub™ Swab, the first and only 3.15 percent Chlorhexidine Gluconate (w/v) and 70 percent Isopropyl Alcohol (v/v) pre-injection skin antiseptic for inclusion in kits. Recognizing the need for clinicians to have the convenience of kits for a variety of medical procedures, PDI®, the Healthcare Division of Nice-Pak Products, Inc., has now made its Chlorascrub™ Swab available to kit manufacturers.

The Chlorascrub™ Swab packaging has been specifically designed to withstand the Ethylene Oxide (EtO) sterilization process for the manufacture of finished sterile kits. PDI® will also continue to market its current FDA-approved non-kit Chlorascrub™ Swab product.

Chlorascrub™ Swab is the optimal, cost-effective delivery system for pre-injection skin preparation. The product achieves a >2 log10 reduction in 30 seconds and maintains a >2 log10 reduction for at least 24 hours. The easy-to-use prep pad design covers a maximum treatment area of 2.5 by 2.5 inches.

For 30 years, PDI® has pioneered the development, testing, manufacturing and marketing of pre-moistened wipes as the optimum delivery system for skin antisepsis, hand hygiene, patient and surface care. With trusted brands including Sani-Cloth®, Sani-Hands®, Sani-Hands® for Kids and Hygea®, and Chlorascrub™, PDI® serves the healthcare market through hospitals, physician and dental offices, emergency medical services, long-term care, schools and a variety of other healthcare facilities. PDI® is the Healthcare Division of Nice-Pak Products Inc., headquartered in Orangeburg, New York. For more information, visit www.pdipdi.com or call Rosica Strategic Public Relations at (201) 843-5600.

ros_admin